| A444 |
Forerunner patent anti-Prominin-1
Featured
|
|
|
| A445 |
AGS-1C4D4
Featured
|
|
|
| A446 |
Inclacumab
Featured
|
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion. |
|
| A447 |
Neihulizumab
Featured
|
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research. |
|
| A448 |
AG02-ADC
Featured
|
|
|
| DC65219 |
ACT-777991
Featured
|
ACT-777991 is an orally active and selective CXCR3 antagonist. ACT-777991 has microsomes and hepatocytes stability across animal models. ACT-777991 inhibits the migration of activated T cells toward CXCL11.
|
|
| DC67080 |
Tri-GalNAc(OAc)3-Perfluorophenyl
Featured
|
Tri-GalNAc(OAc)3-Perfluorophenyl is a pentafluorophenyl modified Tri-GalNAc(OAc)3 (HY-148118), a tri-GalNAc ligand that can be used for the synthesis of GalNAc-LYTAC. GalNAc-LYTAC engages the asialoglycoprotein receptor for targeted protein degradation. tri-GalNAc: triantenerrary N-acetylgalactosamine; LYTAC: lysosome-targeting chimera. |
|
| DC60672 |
BAY-184
Featured
|
BAY-184 is the first, potent and selective acylsulfonamide-benzofuran in vivo-active KAT6A/B inhibitor with IC50 of 71 nM. |
|
| DC67081 |
CY5-SE
Featured
|
Cy5-SE (Cy5 NHS Ester) is a reactive dye for the labeling of amino-groups in peptides, proteins, and oligonucleotides. This dye requires small amount of organic co-solvent (such as DMF or DMSO) to be used in labeling reaction. This reagent is ideal for very cost-efficient labeling of soluble proteins, as well as all kinds of peptides and oligonucleotides. This reagent also works well in organic solvents for small molecule labeling. Excitation (nm):649, Emission (nm): 670. |
|
| DC60674 |
XY-07-191
Featured
|
XY-07-191 is the negative control of XY-07-35. |
|
| DC60675 |
MrTAC-HaXS8
Featured
|
MrTAC-HaXS8 is a methylarginine targeting chimera (MrTAC). MrTAC-HaXS8 induces lysosomal GSK3β proteolysis with DC50 of 11.3 nM. |
|
| DC60676 |
MRT-6160
Featured
|
MRT-6160 is a first-in-class molecular glue degrader that specifically targets VAV1 for proteasomal degradation with DC50 of 7 nM. |
|
| DC60677 |
Compound 31 (MerTK inhibitor)
Featured
|
Compound 31 (MerTK inhibitor) is a potent azetidine-benzoxazole MerTK inhibitor with IC50 of 1.3 nM. Compound 31 potently engages the target in vivo and demonstrates single agent activity in the immune-driven MC-38 murine syngeneic tumor model. |
.jpg)
|
| DC60678 |
ALG-055009
Featured
|
ALG-055009 is a potent and selective thyroid hormone receptor beta (THR-β) agonist with EC50 of 0.063 μM. ALG-055009 is highly metabolically stable, with good permeability and a relatively low efflux ratio. |
|
| DC60679 |
DYR684
Featured
|
DYR684 is a potent, selective, and metabolically stable PROTAC of the protein kinases DYRK1A and DYRK1B with Kd of 6.3 nM and 16 nM, respectively. |
|
| DC67083 |
INDEX NAME NOT YET ASSIGNED
Featured
|
|
|
| DC60680 |
AMG 193
Featured
|
AMG 193 is an orally bioavailable and MTA-cooperative PRMT5 inhibitor with IC50 of 0.107 μM in MTAP-null cells, which is about 40-fold selective over MTAP WT cells. |
|
| DC60681 |
SD-436
Featured
|
SD-436 is a highly potent and selective STAT3 degrader with DC50 of 0.1 nM in human PBMCs and displays >10,000-fold degradation selectivity for STAT3 over other STAT proteins. |
|
| PR0047243 |
ERD-1233
Featured
|
ERD-1233 is a potent and orally efficacious estrogen receptor α (ERα) degrader with DC50 of 0.9 nM. ERD-1233 does not display any liability in CYP inhibition, hERG inhibition, and microsomal and plasma stability. ERD-1233 effectively reduces ER protein in ER+ tumors and achieves tumor regression in the ER wild-type MCF-7 xenograft tumor model.
ERD-1233 is a potent and orally efficacious estrogen receptor α (ERα) degrader with DC50 of 0.9 nM. ERD-1233 does not display any liability in CYP inhibition, hERG inhibition, and microsomal and plasma stability. ERD-1233 effectively reduces ER protein in ER+ tumors and achieves tumor regression in the ER wild-type MCF-7 xenograft tumor model.
|
|
| DC9973 |
Osilodrostat phosphate
Featured
|
Osilodrostat (LCI699) phosphate is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat phosphate is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat phosphate inhibits aldosterone and corticosterone synthesis. Osilodrostat phosphate has blood pressure lowering ability. Osilodrostat phosphate can be used for research of Cushing syndrome (CS). |
|
| DC60687 |
DYR530
Featured
|
DYR530 is a high affinity DYRK1A inhibitor with Kd of 0.91 nM. |
|
| DC60688 |
Gibberellin A3 methyl ester
Featured
|
|
|
| DC60690 |
Gibberellin A4
Featured
|
Gibberellin A4 is a natural compound that can be isolated from Sphaceloma manihoticola. Gibberellin A4 is a causal agent of cassava superelongation disease. |
|
| DC60689 |
Gibberellin A5
Featured
|
Gibberellin A5 is a plant hormone that promotes floral development. |
|
| DC60691 |
Gibberellin A12
Featured
|
|
|
| DC67084 |
gibberellin A12 aldehyde
Featured
|
|
|
| DC67085 |
Gibberellin A19
Featured
|
|
|
| DC67086 |
GIBBERELLIN A20
Featured
|
|
|
| DC67087 |
2β,3β,4aα-Trihydroxy-1β-methyl-8-methylenegibbane-1α,10β-dicarboxylic acid 1,4a-lactone
Featured
|
|
|
| DC67088 |
Gibberellin 44
Featured
|
|
|
